At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 121 enrolled
Drug / intervention
zoledronic aciddrug
Likely dose
zoledronic acid 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bone Marker-directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma.
In Brief
A Phase 4 clinical trial evaluating zoledronic acid for Multiple Myeloma. Completed, enrolled 121 participants across 42 sites.
Detailed Summary
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to two years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedFeb 2008
Primary CompletionApr 2012
TodayJul 2026
First PostedFeb 25, 2008
Enrollment StartNov 7, 2007
Primary CompletionApr 3, 2012
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 18.4 years ago
Interventions
zoledronic aciddrug
Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.